Blog
Kaiser Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral
Published February 19, 2021
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam…
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? Not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for >90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%).
Recommended
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for InnovationMay 21, 2025 | 1:00 - 1:45 PM ET
Webinars
Enabling Contract Administration Capabilities
Available On Demand
Are you a leader in a pre-commercial company evaluating your contract administration needs? Are you a leader in a commercial company struggling with manual contract administration processes? If either scenario sounds familiar, watch our latest webinar, Enabling Contract Administration Capabilities. TGaS Advisors, a division of Trinity Life Sciences, has designed this webinar specifically for Market Access and Contracting leaders in pre-commercial and emerging life science companies. During the webinar, we discuss industry best practices and approaches for building and optimizing…
Blog
The Future of Cell Therapy: What’s Next?
Published November 3, 2020
Executive Summary Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially To date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approval There have been multiple challenges involved when trying to successfully commercialize the products, but the landscape looks…
Blog
ICER Released First Cost-Effectiveness Assessment for a Digital Therapeutic (DTx)
Published November 3, 2020
Written by Tom Rutkowski and Patrick Buck…
Webinars
COVID-19 Impact on Launch Performance
Available On Demand
How has COVID-19 impacted launch performance and timing? Pharmaceutical leaders are facing some of the toughest challenges of their careers when it comes to launching in the midst of COVID-19. With so much at stake and so much uncertainty, companies are looking for fact-based insights to power their decision-making. Trinity has done an in-depth evaluation of the impact of COVID-19 on launch performance and timing. We have compared forecasted/expected revenue to actual revenue for products that launched within six months…
Webinars
COVID-19 Forecasting: Seeking Clarity in a World of Uncertainty
Available On Demand
Forecasters in the life sciences industry are facing novel challenges in the midst of the COVID-19 pandemic. With so much at stake, and so much change, forecasting in this environment is both vital and difficult. Companies are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making. Key Takeaways Insights into assumptions that are critical to projecting the future of the COVID-19 pandemic. Examples of how different scenarios…
Blog
FDA Launches the Digital Health Center of Excellence
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Blog
CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA
Published September 22, 2020
Executive Summary Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Case Studies
Early Payer Guidance Across Four Inflammatory Disease Areas
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas. Geographic Scope: Client Situation The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making. Trinity’s Solution Trinity conducted comprehensive secondary research in the following areas: Disease background including diagnosis, prognosis, epidemiology and unmet needsCurrent and future paradigm including lines of therapies and standard of carePipeline analysis including key therapies in development and future treatment gamechangersPricing and access landscape including pricing analysis, health…
Blog
Ten Long-Term Impacts of COVID-19 on Biopharma
Published August 25, 2020
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…